Introduction: We provide a single-institution comparison of open, conventional laparoscopic (CL) and laparoendoscopic single-site (LESS) nephrectomy in children.

Methods: We identified all nephrectomy cases occurring at Rady Children's Hospital from July 2007 to March 2010. Exclusion criteria included redo/bilateral operations, malignancy, transplant nephrectomy, or complex urogenital anomalies. We compared patient demographics, total operative times, estimated blood loss (EBL), length of stay (LOS), complication rates, postoperative pain score, narcotic usage, and total hospital costs.

Results: We identified 7 LESS, 11 CL, and 8 open nephrectomy patients who met our criteria. The mean age of patients was 8.5, 7.3, and 4.2 years for LESS, CL, and open nephrectomy, respectively (P=.217). Operative times were 192.2, 219.3, and 127.4 minutes for LESS, CL, and open nephrectomy, respectively (P=.076). EBL was 15, 13.2, and 12.5 mL, respectively, for these groups (P=.871). There were no complications in any of the groups, although 1 LESS patient required conversion to open nephrectomy for bleeding. Mean LOS was 46.8, 36.9, and 33.8 hours in the LESS, CL, and open nephrectomy groups (P=.308). Mean pain scores on postoperative day 1 were 2.3, 1.8, and 1.6 in each group, respectively (P=.518). Hospital costs were comparable between the LESS and CL groups. The mean cost for open nephrectomy was 54.4% the mean cost for CL, however (P=.001).

Conclusions: LESS nephrectomy in children is safe and overall comparable with CL. In our experience, no modality confers a distinct advantage except for the decreased cost associated with open surgery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2010.11.030DOI Listing

Publication Analysis

Top Keywords

open nephrectomy
28
nephrectomy
11
open
9
laparoendoscopic single-site
8
conventional laparoscopic
8
operative times
8
comparison laparoendoscopic
4
single-site conventional
4
laparoscopic open
4
nephrectomy pediatric
4

Similar Publications

Partial nephrectomy has become the gold standard treatment for small renal masses. This study aimed to assess the impact of soft coagulation hemostasis on parenchymal volume reduction of the operated kidney after an open partial nephrectomy. We retrospectively reviewed 94 patients with small renal tumors who underwent open partial nephrectomy with soft-coagulation hemostasis at our institution.

View Article and Find Full Text PDF

Background: Renal cell carcinoma (RCC) is a common malignancy, and nephrectomy is the mainstay of treatment for non-metastatic disease. The choice of surgery depends on the risks of oncologic recurrence, kidney function decline, and perioperative complications. This study aimed to identify factors associated with adverse post-operative outcomes in RCC patients undergoing nephrectomy at Townsville University Hospital (TUH).

View Article and Find Full Text PDF

Rare Renal Malignancies: A Case Series Highlighting Uncommon Presentations and Their Management Strategies.

Cureus

December 2024

Department of Urology, Mamata Academy of Medical Sciences, Bachupally, IND.

This case series elucidates renal cell carcinoma characterized by three distinct presentations, necessitating individualized treatment strategies tailored to each specific circumstance. The three cases presented pertain to clear cell renal cell carcinoma. The first case involves a 44-year-old male patient with renal cell carcinoma in an ectopic kidney, an exceedingly rare occurrence with limited literature.

View Article and Find Full Text PDF

Background And Objective: Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study.

Methods: Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC.

View Article and Find Full Text PDF

Clear cell renal cell carcinoma is the predominant subtype of kidney cancer. With distant metastasis, the overall survival rate for patients with renal cell carcinoma decreases significantly compared to localized disease. However, pembrolizumab plus axitinib combination is safe and improves long-term survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!